Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2017-09-27 Regulatory Filings
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document announces specific corporate developments: regulatory approval in Russia and guidance published by NICE (UK) for the use of Echopulse®. These announcements relate to market access and regulatory milestones for a medical device. This type of specific, non-financial, operational/regulatory update that doesn't fit into standard financial reports (10-K, IR, ER) or governance documents (DEF 14A, CGR) is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory Update (LTR) if it were about a dispute. Since it is a positive regulatory achievement announcement, RNS serves as the most appropriate general regulatory announcement category, as it is not a formal financial report, management change, or dividend notice. The length is moderate, but the content is purely informational about regulatory status, not a comprehensive report.
2017-09-27 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated September 27, 2017, announcing two key developments for Theraclion: 1) The UK's NICE published recommendations for the use of its Echopulse® device for breast fibroadenoma, and 2) The company obtained regulatory approval from the Russian Ministry of Health for the Echopulse® system. This content focuses on market access expansion and regulatory milestones, which are typical components of general corporate news or regulatory updates, rather than a specific periodic financial report (like 10-K or IR) or a management discussion (MDA). Since it is an announcement detailing regulatory achievements and market access progress, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, although it touches upon regulatory matters. Given the options, RNS serves as the most appropriate catch-all for significant, non-financial-reporting corporate news that isn't explicitly covered by other codes like MANG or CAP. It is not a formal financial report, earnings release, or management discussion.
2017-09-27 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated September 25, 2017, announcing several operational and market achievements for Theraclion, including new insurance coverage in Germany, the first treatments in a Hong Kong hospital, and winning an award. This type of announcement, detailing business updates, market penetration, and non-financial awards, is characteristic of a general corporate announcement or press release. It is not a formal regulatory filing like a 10-K, 10-Q (IR), or a specific financial report (ER, AR). Since it details business progress and market access achievements, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, although it could also be considered a type of Investor Presentation (IP) if it were more structured for investors, but its format strongly suggests a press release. Given the options, and since it is a general announcement of business milestones rather than a specific financial report or mandatory filing, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it shares characteristics with an Earnings Release (ER) in terms of timing (though not focused on financial results). However, looking closely at the definitions, this is a general corporate news announcement. Since there is no specific code for 'Press Release' or 'News Announcement', RNS (Regulatory Filings) serves as the best general category for non-standard, timely corporate communications.
2017-09-25 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated September XX, 2017, announcing business developments, including expanded insurance coverage in Germany, the launch of treatments in a Hong Kong hospital, and winning a Silver Stevie Award. It is not a formal regulatory filing like a 10-K, nor is it a comprehensive quarterly report (IR) or an earnings release (ER) which typically focuses strictly on financial figures. It is an announcement detailing operational milestones and business progress, which aligns best with a general Regulatory Filing (RNS) as a catch-all for important, non-standard announcements, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate general category for corporate news releases that don't fit the highly specific financial/governance codes. Since it is a news announcement about business progress rather than a formal financial report or governance document, RNS is the best fit.
2017-09-25 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated September 11, 2017, announcing the rationale and design of a new clinical study combining Theraclion's echotherapy (HIFU) with pembrolizumab for metastatic breast cancer. It details the study objectives, methodology (two arms, 12 patients), and quotes company management and the principal investigator. This type of announcement, detailing a new clinical trial or significant operational/scientific development, is typically classified as a general press release or regulatory announcement. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a management discussion (MDA), nor a specific legal/governance filing, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for non-standard corporate announcements, or potentially an Investor Presentation (IP) if it were structured as slides, but here it reads like a news release. Given the context of a press release detailing scientific progress and upcoming trials, RNS is the most appropriate general classification for a non-standard corporate update.
2017-09-11 French
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 90% confidence The document is a press release dated September 11th, 2017, discussing the rationale and design of a new clinical trial combining Echotherapy (HIFU) and immunotherapy (pembrolizumab) for metastatic breast cancer. It features quotes from the CEO and the co-lead investigator, outlines trial objectives, and provides company background. This content is characteristic of an announcement regarding ongoing research, clinical development, or strategic updates, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it details a significant clinical development and strategy update aimed at investors and the public, it aligns best with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the detailed discussion of the trial design, objectives, and scientific rationale, it functions as an investor communication piece detailing future strategy and progress, making 'Investor Presentation' (IP) a strong fit, although it is formatted as a press release. However, since it is not a formal presentation deck but a news announcement about a trial, and it doesn't fit the other specific categories (like M&A, Capital Change, or Earnings), the most appropriate general category for significant, non-standard corporate news is 'Regulatory Filings' (RNS) as a fallback, or potentially 'Investor Presentation' (IP) if we interpret the content as the substance that would typically be presented to investors. Given the context of clinical trial updates, which are often shared via press release but contain detailed information, I will classify it as an Investor Presentation (IP) as it is highly focused on communicating clinical progress to the investment community, even if it's not a slide deck.
2017-09-11 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.